Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2014 (2014), Article ID 564296, 15 pages
http://dx.doi.org/10.1155/2014/564296
Review Article

Control of the Inflammatory Response Mechanisms Mediated by Natural and Induced Regulatory T-Cells in HCV-, HTLV-1-, and EBV-Associated Cancers

1CNRS UMR 8161, Institut de Biologie de Lille, Universit Lille-Nord de France, SIRIC ONCOLille, Institut Pasteur de Lille, IFR142, 1 rue du Professeur Calmette, 59021 Lille Cedex, France
2UFR de Biologie, Université de Lille 1, Cité Scientifique, Bâtiment SN3, 59655 Villeneuve d’Ascq Cedex, France

Received 14 March 2014; Revised 18 June 2014; Accepted 30 July 2014; Published 30 November 2014

Academic Editor: Constantino López-Macías

Copyright © 2014 Laurissa Ouaguia et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. http://www.who.int/cancer/en/.
  2. F. Balkwill and A. Mantovani, “Inflammation and cancer: back to virchow?” The Lancet, vol. 357, no. 9255, pp. 539–545, 2001. View at Publisher · View at Google Scholar · View at Scopus
  3. H. Kuper, H.-O. Adami, and D. Trichopoulos, “Infections as a major preventable cause of human cancer,” Journal of Internal Medicine, vol. 248, no. 3, pp. 171–183, 2000. View at Publisher · View at Google Scholar · View at Scopus
  4. Q. Chang, Y.-K. Wang, Q. Zhao, C.-Z. Wang, Y.-Z. Hu, and B.-Y. Wu, “Th17 cells are increased with severity of liver inflammation in patients with chronic hepatitis C,” Journal of Gastroenterology and Hepatology, vol. 27, no. 2, pp. 273–278, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. T. J. Liang and T. Heller, “Pathogenesis of hepatitis C-associated hepatocellular carcinoma,” Gastroenterology, vol. 127, pp. S62–S71, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. N. Araya, T. Sato, N. Yagishita et al., “Human T-lymphotropic virus type 1 (HTLV-1) and regulatory T cells in HTLV-1-associated neuroinflammatory disease,” Viruses, vol. 3, no. 9, pp. 1532–1548, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. L. M. Coussens and Z. Werb, “Inflammation and cancer,” Nature, vol. 420, no. 6917, pp. 860–867, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. X. Chen, S. A. Kamranvar, and M. G. Masucci, “Tumor viruses and replicative immortality—avoiding the telomere hurdle,” Seminars in Cancer Biology, vol. 26, pp. 43–51, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. E. Thomas, V. D. Gonzalez, Q. Li et al., “HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons,” Gastroenterology, vol. 142, no. 4, pp. 978–988, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. W. Zou and N. P. Restifo, “TH17 cells in tumour immunity and immunotherapy,” Nature Reviews Immunology, vol. 10, no. 4, pp. 248–256, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Sakaguchi, K. Wing, Y. Onishi, P. Prieto-Martin, and T. Yamaguchi, “Regulatory T cells: How do they suppress immune responses?” International Immunology, vol. 21, no. 10, pp. 1105–1111, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Busca and A. Kumar, “Innate immune responses in hepatitis B virus (HBV) infection,” Virology Journal, vol. 11, no. 1, article 22, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. J. Pawlotski, “Virus de l'hépatite C et réponse immunitaire,” Gastroentérologie Clinique et Biologique, vol. 24, no. 4, p. 123, 2001. View at Google Scholar
  14. M. Karin and F. R. Greten, “NF-κB: Linking inflammation and immunity to cancer development and progression,” Nature Reviews Immunology, vol. 5, no. 10, pp. 749–759, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. (MIT) satMIoT, “Inflammationcancer link confirmed,” Nature Reviews Immunology, vol. 8, no. 7, p. 494, 2008. View at Publisher · View at Google Scholar
  16. B. B. Aggarwal, S. Shishodia, S. K. Sandur, M. K. Pandey, and G. Sethi, “Inflammation and cancer: how hot is the link?” Biochemical Pharmacology, vol. 72, no. 11, pp. 1605–1621, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. J. P. O'Connor, M. B. Manigrasso, B. D. Kim, and S. Subramanian, “Fracture healing and lipid mediators,” BoneKEy Reports, vol. 3, p. 517, 2014. View at Publisher · View at Google Scholar
  18. T. Ishida and R. Ueda, “CCR4 as a novel molecular target for immunotherapy of cancer,” Cancer Science, vol. 97, no. 11, pp. 1139–1146, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. R. A. Flavell, S. Sanjabi, S. H. Wrzesinski, and P. Licona-Limón, “The polarization of immune cells in the tumour environment by TGFβ,” Nature Reviews Immunology, vol. 10, no. 8, pp. 554–567, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. H. Nishikawa and S. Sakaguchi, “Regulatory T cells in cancer immunotherapy,” Current Opinion in Immunology, vol. 27, no. 1, pp. 1–7, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. M. A. Vadas, J. F. A. P. Miller, I. F. C. McKenzie et al., “Ly and Ia antigen phenotypes of T cells involved in delayed type hypersensitivity and in suppression,” Journal of Experimental Medicine, vol. 144, no. 1, pp. 10–19, 1976. View at Publisher · View at Google Scholar · View at Scopus
  22. S. Sakaguchi, N. Sakaguchi, M. Asano, M. Itoh, and M. Toda, “Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases,” Journal of Immunology, vol. 155, no. 3, pp. 1151–1164, 1995. View at Google Scholar · View at Scopus
  23. S. Hori, T. Takahashi, and S. Sakaguchi, “Control of autoimmunity by naturally arising regulatory CD4+ T cells,” Advances in Immunology, vol. 81, pp. 331–371, 2003. View at Publisher · View at Google Scholar · View at Scopus
  24. J. Shimizu, S. Yamazaki, T. Takahashi, Y. Ishida, and S. Sakaguchi, “Stimulation of CD25+CD4+ regulatory T cells through GITR breaks immunological self-tolerance,” Nature Immunology, vol. 3, no. 2, pp. 135–142, 2002. View at Publisher · View at Google Scholar · View at Scopus
  25. G. A. M. Povoleri, C. Scottá, E. A. Nova-Lamperti, S. John, G. Lombardi, and B. Afzali, “Thymic versus induced regulatory T cells-who regulates the regulators?” Frontiers in Immunology, vol. 4, article 169, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. C. Baecher-Allan, E. Wolf, and D. A. Hafter, “MHC class II expression identifies functionally distinct human regulatory T cells,” Journal of Immunology, vol. 176, no. 8, pp. 4622–4631, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. S. Beissert, A. Schwarz, and T. Schwarz, “Regulatory T cells,” Journal of Investigative Dermatology, vol. 126, no. 1, pp. 15–24, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. F. Bolacchi, A. Sinistro, C. Ciaprini et al., “Increased hepatitis C virus (HCV)-specific CD4+CD25+ regulatory T lymphocytes and reduced HCV-specific CD4+ T cell response in HCV-infected patients with normal versus abnormal alanine aminotransferase levels,” Clinical and Experimental Immunology, vol. 144, no. 2, pp. 188–196, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Deaglio, K. M. Dwyer, W. Gao et al., “Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression,” Journal of Experimental Medicine, vol. 204, no. 6, pp. 1257–1265, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. W. Liu, A. L. Putnam, Z. Xu-yu et al., “CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells,” The Journal of Experimental Medicine, vol. 203, no. 7, pp. 1701–1711, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. E. M. Shevach, “Mechanisms of foxp3+ T regulatory cell-mediated suppression,” Immunity, vol. 30, no. 5, pp. 636–645, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Fabien, M. Olivier, G. Khaldoun et al., “CD49b, a major marker of regulatory T-cells type 1, predicts the response to antiviral therapy of recurrent hepatitis C after liver transplantation,” BioMed Research International, vol. 2014, Article ID 290878, 9 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  33. M. G. Roncarolo, S. Gregori, M. Battaglia, R. Bacchetta, K. Fleischhauer, and M. K. Levings, “Interleukin-10-secreting type 1 regulatory T cells in rodents and humans,” Immunological Reviews, vol. 212, no. 1, pp. 28–50, 2006. View at Publisher · View at Google Scholar
  34. Y. Y. Wan and R. A. Flavell, “Regulatory T-cell functions are subverted and converted owing to attenuated Foxp3 expression,” Nature, vol. 445, no. 7129, pp. 766–770, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. L. W. Collison, V. Chaturvedi, A. L. Henderson et al., “IL-35-mediated induction of a potent regulatory T cell population,” Nature Immunology, vol. 11, no. 12, pp. 1093–1101, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. E. Sato, S. H. Olson, J. Ahn et al., “Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, pp. 18538–18543, 2005. View at Google Scholar
  37. N. Kobayashi, N. Hiraoka, W. Yamagami et al., “FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis,” Clinical Cancer Research, vol. 13, no. 3, pp. 902–911, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. M. Kim, T. Grimmig, M. Grimm et al., “Expression of Foxp3 in colorectal cancer but not in Treg cells correlates with disease progression in patients with colorectal cancer,” PLoS ONE, vol. 8, no. 1, Article ID e53630, 2013. View at Publisher · View at Google Scholar · View at Scopus
  39. T. L. Whiteside, “Disarming suppressor cells to improve immunotherapy,” Cancer Immunology, Immunotherapy, vol. 61, no. 2, pp. 283–288, 2012. View at Publisher · View at Google Scholar · View at Scopus
  40. C. C. Chang, R. Ciubotariu, J. S. Manavalan et al., “Tolerization of dendritic cells by Ts cells: the crucial role of inhibitory receptors ILT3 and ILT4,” Nature Immunology, vol. 3, no. 3, pp. 237–243, 2002. View at Publisher · View at Google Scholar · View at Scopus
  41. S. Strober, L. Cheng, D. Zeng et al., “Double negative (CD4-CD8-αβ+) T cells which promote tolerance induction and regulate autoimmunity,” Immunological Reviews, no. 149, pp. 217–230, 1996. View at Google Scholar · View at Scopus
  42. R. A. Peterson, “Regulatory T-cells: diverse phenotypes integral to immune homeostasis and suppression,” Toxicologic Pathology, vol. 40, no. 2, pp. 186–204, 2012. View at Publisher · View at Google Scholar · View at Scopus
  43. T. Kushida, M. Inaba, K. Takeuchi, K. Sugiura, R. Ogawa, and S. Ikehara, “Treatment of intractable autoimmune diseases in MRL/lpr mice using a new strategy for allogeneic bone marrow transplantation,” Blood, vol. 95, no. 5, pp. 1862–1868, 2000. View at Google Scholar · View at Scopus
  44. J. A. Kapp and Y. Ke, “The role of γδ TCR-bearing T cells in oral tolerance,” Research in Immunology, vol. 148, no. 8-9, pp. 561–567, 1997. View at Publisher · View at Google Scholar · View at Scopus
  45. F. E. Leal, L. C. Ndhlovu, A. M. Hasenkrug et al., “Expansion in CD39(+) CD4(+) immunoregulatory t cells and rarity of Th17 cells in HTLV-1 infected patients is associated with neurological complications,” PLoS Neglected Tropical Diseases, vol. 7, no. 2, Article ID e2028, 2013. View at Publisher · View at Google Scholar · View at Scopus
  46. N. Delhem, F. Cottrez, A. Carpentier et al., “Role of the regulatory T lymphocytes in hepatitis C fibrosis progression,” Bulletin du Cancer, vol. 95, no. 11, pp. 1029–1038, 2008. View at Publisher · View at Google Scholar · View at Scopus
  47. A. Carpentier, F. Conti, M. Carrière et al., “Analysis of gene transcription in sera during chronic hepatitis C infection,” Journal of Medical Virology, vol. 81, no. 3, pp. 473–480, 2009. View at Publisher · View at Google Scholar · View at Scopus
  48. N. M. Dhafer Mrizak, N. Wambre, L. Ouaguia et al., “Nasopharyngeal carcinoma-derived exosomes recruit, expand and upregulate biological activities of human regulatory T cells (Treg),” Journal of Extracellular Vesicles, vol. 1, p. 18182, 2012. View at Google Scholar
  49. D. Camarillo, R. Banerjee, T. L. Greenhow, and J. H. Tureen, “Group B streptococcal endocarditis after elective abortion in an adolescent,” Pediatric Infectious Disease Journal, vol. 28, no. 1, pp. 67–69, 2009. View at Publisher · View at Google Scholar · View at Scopus
  50. N. Hiraoka, K. Onozato, T. Kosuge, and S. Hirohashi, “Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions,” Clinical Cancer Research, vol. 12, no. 18, pp. 5423–5434, 2006. View at Publisher · View at Google Scholar · View at Scopus
  51. L. Ouaguia, O. Morales, D. Mrizak et al., “Overexpression of regulatory T cells type 1 (Tr1) specific markers in a patient with HCV-induced hepatocellular carcinoma,” ISRN Hepatology, vol. 2013, Article ID 928485, 7 pages, 2013. View at Publisher · View at Google Scholar
  52. N. R. West, S. E. Kost, S. D. Martin et al., “Tumour-infiltrating FOXP3+ lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptor-negative breast cancer,” British Journal of Cancer, vol. 108, no. 1, pp. 155–162, 2013. View at Publisher · View at Google Scholar · View at Scopus
  53. D. J. Campbell and M. A. Koch, “Phenotypical and functional specialization of FOXP3+ regulatory T cells,” Nature Reviews Immunology, vol. 11, no. 2, pp. 119–130, 2011. View at Publisher · View at Google Scholar · View at Scopus
  54. J. M. Llovet, A. Burroughs, and J. Bruix, “Hepatocellular carcinoma,” The Lancet, vol. 362, no. 9399, pp. 1907–1917, 2003. View at Publisher · View at Google Scholar · View at Scopus
  55. S. F. Altekruse, K. A. McGlynn, and M. E. Reichman, “Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005,” Journal of Clinical Oncology, vol. 27, no. 9, pp. 1485–1491, 2009. View at Publisher · View at Google Scholar · View at Scopus
  56. F. X. Bosch, J. Ribes, M. Díaz, and R. Cléries, “Primary liver cancer: worldwide incidence and trends,” Gastroenterology, vol. 127, pp. S5–S16, 2004. View at Publisher · View at Google Scholar · View at Scopus
  57. J. M. Llovet and J. Bruix, “Molecular targeted therapies in hepatocellular carcinoma,” Hepatology, vol. 48, no. 4, pp. 1312–1327, 2008. View at Publisher · View at Google Scholar · View at Scopus
  58. M. M. Hassan, A. Frome, Y. Z. Patt, and H. B. El-Serag, “Rising prevalence of hepatitis C virus infection among patients recently diagnosed with hepatocellular carcinoma in the United States,” Journal of Clinical Gastroenterology, vol. 35, no. 3, pp. 266–269, 2002. View at Publisher · View at Google Scholar · View at Scopus
  59. G. M. Lauer and B. D. Walker, “Hepatitis C virus infection,” The New England Journal of Medicine, vol. 345, no. 1, pp. 41–52, 2001. View at Publisher · View at Google Scholar · View at Scopus
  60. Y. Hoshida, A. Villanueva, M. Kobayashi et al., “Gene expression in fixed tissues and outcome in hepatocellular carcinoma,” The New England Journal of Medicine, vol. 359, no. 19, pp. 1995–2004, 2008. View at Publisher · View at Google Scholar · View at Scopus
  61. A. Fourniller-Jacob, M. Girard, and C. Wychowski, “Infection par le virus de l'hépatite C et réponse immunitaire: application au diagnostic et à la vaccination,” Virologie, vol. 1, no. 3, pp. 217–228, 1997. View at Google Scholar
  62. P. A. Knolle and R. Thimme, “Hepatic immune regulation and its involvement in viral hepatitis infection,” Gastroenterology, vol. 146, no. 5, pp. 1193–1207, 2014. View at Publisher · View at Google Scholar · View at Scopus
  63. W. Wu, J. Li, F. Chen, H. Zhu, G. Peng, and Z. Chen, “Circulating Th17 cells frequency is associated with the disease progression in HBV infected patients,” Journal of Gastroenterology and Hepatology, vol. 25, no. 4, pp. 750–757, 2010. View at Publisher · View at Google Scholar · View at Scopus
  64. J.-P. Zhang, J. Yan, J. Xu et al., “Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients,” Journal of Hepatology, vol. 50, no. 5, pp. 980–989, 2009. View at Publisher · View at Google Scholar · View at Scopus
  65. M. Numasaki, J.-I. Fukushi, M. Ono et al., “Interleukin-17 promotes angiogenesis and tumor growth,” Blood, vol. 101, no. 7, pp. 2620–2627, 2003. View at Publisher · View at Google Scholar · View at Scopus
  66. I. Kryczek, S. Wei, L. Zou et al., “Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment,” Journal of Immunology, vol. 178, no. 11, pp. 6730–6733, 2007. View at Publisher · View at Google Scholar · View at Scopus
  67. J. Yang, J.-X. Zhang, H. Wang, G.-L. Wang, Q.-G. Hu, and Q.-C. Zheng, “Hepatocellular carcinoma and macrophage interaction induced tumor immunosuppression via treg requires TLR4 signaling,” World Journal of Gastroenterology, vol. 18, no. 23, pp. 2938–2947, 2012. View at Publisher · View at Google Scholar · View at Scopus
  68. J.-I. Riezu-Boj, E. Larrea, R. Aldabe et al., “Hepatitis C virus induces the expression of CCL17 and CCL22 chemokines that attract regulatory T cells to the site of infection,” Journal of Hepatology, vol. 54, no. 3, pp. 422–431, 2011. View at Publisher · View at Google Scholar · View at Scopus
  69. A. Budhu and X. W. Wang, “The role of cytokines in hepatocellular carcinoma,” Journal of Leukocyte Biology, vol. 80, no. 6, pp. 1197–1213, 2006. View at Publisher · View at Google Scholar · View at Scopus
  70. A. R. Lopes, P. Kellam, A. Das et al., “Bim-mediated deletion of antigen-specific CD8+ T cells in patients unable to control HBV infection,” Journal of Clinical Investigation, vol. 118, no. 5, pp. 1835–1845, 2008. View at Publisher · View at Google Scholar · View at Scopus
  71. J. Haybaeck, N. Zeller, M. J. Wolf et al., “A lymphotoxin-driven pathway to hepatocellular carcinoma,” Cancer Cell, vol. 16, no. 4, pp. 295–308, 2009. View at Publisher · View at Google Scholar · View at Scopus
  72. M. S. N. Ramzan, M. A. Thélu, C. Guillermet et al., “Intra-hepatic lymphocytes in HCV-related cirrhosis and hepatocellular carcinoma,” Gut, 2012. View at Google Scholar
  73. H. Ito, M. Hoshi, H. Ohtaki et al., “Ability of IDO to attenuate liver injury in α-galactosylceramide- induced hepatitis model,” Journal of Immunology, vol. 185, no. 8, pp. 4554–4560, 2010. View at Publisher · View at Google Scholar · View at Scopus
  74. A. Das, M. Hoare, N. Davies et al., “Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection,” Journal of Experimental Medicine, vol. 205, no. 9, pp. 2111–2124, 2008. View at Publisher · View at Google Scholar · View at Scopus
  75. S. Cooper, A. L. Erickson, E. J. Adams et al., “Analysis of a successful immune response against hepatitis C virus,” Immunity, vol. 10, no. 4, pp. 439–449, 1999. View at Publisher · View at Google Scholar · View at Scopus
  76. P. Knolle, J. Schlaak, A. Uhrig, P. Kempf, K.-H. Meyer zum Buschenfelde, and G. Gerken, “Human Kupffer cells secrete IL-10 in response to lipopolysaccharide (LPS) challenge,” Journal of Hepatology, vol. 22, no. 2, pp. 226–229, 1995. View at Publisher · View at Google Scholar · View at Scopus
  77. B. Bengsch, B. Seigel, M. Ruhl et al., “Coexpression of PD-1, 2B4, CD160 and KLRG1 on exhausted HCV-specific CD8+ T cells is linked to antigen recognition and T cell differentiation,” PLoS Pathogens, vol. 6, no. 6, 2010. View at Publisher · View at Google Scholar · View at Scopus
  78. M. M. Lai and C. F. Ware, “Hepatitis C virus core protein: possible roles in viral pathogenesis,” Current Topics in Microbiology and Immunology, vol. 242, pp. 117–134, 2000. View at Google Scholar
  79. D. J. Kittlesen, K. A. Chianese-Bullock, Z. Q. Yao, T. J. Braciale, and Y. S. Hahn, “Interaction between complement receptor gC1qR and hepatitis C virus core protein inhibits T-lymphocyte proliferation,” The Journal of Clinical Investigation, vol. 106, no. 10, pp. 1239–1249, 2000. View at Publisher · View at Google Scholar · View at Scopus
  80. G. Gong, G. Waris, R. Tanveer, and A. Siddiqui, “Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-κB,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 17, pp. 9599–9604, 2001. View at Publisher · View at Google Scholar · View at Scopus
  81. N. Pavio, P. R. Romano, T. M. Graczyk, S. M. Feinstone, and D. R. Taylor, “Protein synthesis and endoplasmic reticulum stress can be modulated by the hepatitis C virus envelope protein E2 through the eukaryotic initiation factor 2α kinase PERK,” Journal of Virology, vol. 77, no. 6, pp. 3578–3585, 2003. View at Publisher · View at Google Scholar · View at Scopus
  82. M. A. Sarhan, A. Y. Chen, and T. I. Michalak, “Differential expression of candidate virus receptors in human T lymphocytes prone or resistant to infection with patient-derived hepatitis C virus,” PLoS ONE, vol. 8, no. 4, Article ID e62159, 2013. View at Publisher · View at Google Scholar · View at Scopus
  83. N. Kakita, T. Kanto, I. Itose et al., “Comparative analyses of regulatory T cell subsets in patients with hepatocellular carcinoma: a crucial role of CD25FOXP3 T cells,” International Journal of Cancer, vol. 131, no. 11, pp. 2573–2583, 2012. View at Publisher · View at Google Scholar · View at Scopus
  84. J. Fu, D. Xu, Z. Liu et al., “Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients,” Gastroenterology, vol. 132, no. 7, pp. 2328–2339, 2007. View at Publisher · View at Google Scholar · View at Scopus
  85. E. Unitt, S. M. Rushbrook, A. Marshall et al., “Compromised lymphocytes infiltrate hepatocellular carcinoma: the role of T-regulatory cells,” Hepatology, vol. 41, no. 4, pp. 722–730, 2005. View at Publisher · View at Google Scholar · View at Scopus
  86. Y. Yi, H.-W. He, J.-X. Wang et al., “The functional impairment of HCC-infiltrating γδ T cells, partially mediated by regulatory T cells in a TGFβ- and IL-10-dependent manner,” Journal of Hepatology, vol. 58, no. 5, pp. 977–983, 2013. View at Publisher · View at Google Scholar · View at Scopus
  87. S. M. Rushbrook, S. M. Ward, E. Unitt et al., “Regulatory T cells suppress in vitro proliferation of virus-specific CD8+ T cells during persistent hepatitis C virus infection,” Journal of Virology, vol. 79, no. 12, pp. 7852–7859, 2005. View at Publisher · View at Google Scholar · View at Scopus
  88. D. Accapezzato, V. Francavilla, M. Paroli et al., “Hepatic expansion of a virus-specific regulatory CD8(+) T cell population in chronic hepatitis C virus infection,” The Journal of Clinical Investigation, vol. 113, pp. 963–972, 2004. View at Google Scholar
  89. A. J. MacDonald, M. Duffy, M. T. Brady et al., “CD4 T helper type 1 and regulatory T cells induced against the same epitopes on the core protein in hepatitis C virus-infected persons,” Journal of Infectious Diseases, vol. 185, no. 6, pp. 720–727, 2002. View at Publisher · View at Google Scholar · View at Scopus
  90. J. H. Wang, M. J. Pianko, X. Ke et al., “Characterization of antigenic variants of hepatitis C virus in immune evasion,” Virology Journal, vol. 8, article 377, 2011. View at Publisher · View at Google Scholar · View at Scopus
  91. X. J. Ji, C. J. Ma, J. M. Wang et al., “HCV-infected hepatocytes drive CD4+CD25+Foxp3+ regulatory T-cell development through the Tim-3/Gal-9 pathway,” European Journal of Immunology, vol. 43, no. 2, pp. 458–467, 2013. View at Publisher · View at Google Scholar · View at Scopus
  92. C. H. T. Hall, R. Kassel, R. S. Tacke, and Y. S. Hahn, “HCV+ hepatocytes induce human regulatory CD4+ T cells through the production of TGF-β,” PLoS ONE, vol. 5, no. 8, Article ID e12154, 2010. View at Publisher · View at Google Scholar · View at Scopus
  93. E. Billerbeck, H. E. Blum, and R. Thimme, “Parallel expansion of human virus-specific FoxP3- effector memory and de novo-generated FoxP3+ regulatory CD8+ T cells upon antigen recognition in vitro,” Journal of Immunology, vol. 179, no. 2, pp. 1039–1048, 2007. View at Publisher · View at Google Scholar · View at Scopus
  94. M. Abel, D. Séne, S. Pol et al., “Intrahepatic virus-specific IL-10-producing CD8 T cells prevent liver damage during chronic hepatitis C virus infection,” Hepatology, vol. 44, no. 6, pp. 1607–1616, 2006. View at Publisher · View at Google Scholar · View at Scopus
  95. K. Takatsuki, “Adult T-cell leukemia/lymphoma,” Nihon Naika Gakkai Zasshi, vol. 74, no. 9, pp. 1210–1213, 1985. View at Publisher · View at Google Scholar · View at Scopus
  96. G. de The and R. Bomford, “An HTLV-I vaccine: why, how, for whom?” AIDS Research and Human Retroviruses, vol. 9, no. 5, pp. 381–386, 1993. View at Publisher · View at Google Scholar · View at Scopus
  97. H. Matsuzaki, K. Yamaguchi, T. Kagimoto, R. Nakai, K. Takatsuki, and W. Oyama, “Monoclonal gammopathies in adult T-cell leukemia,” Cancer, vol. 56, pp. 1380–1383, 1985. View at Publisher · View at Google Scholar
  98. K. Nakada, K. Yamaguchi, S. Furugen et al., “Monoclonal integration of HTLV-I proviral DNA in patients with strongyloidiasis,” International Journal of Cancer, vol. 40, no. 2, pp. 145–148, 1987. View at Publisher · View at Google Scholar · View at Scopus
  99. S. Y. Lee, K. Mastushita, J. Machida, M. Tajiri, K. Yamaguchi, and K. Takatsuki, “Human T-cell leukemia virus type I infection in hemodialysis patients,” Cancer, vol. 60, no. 7, pp. 1474–1478, 1987. View at Google Scholar · View at Scopus
  100. K. Ohshima, “Pathological features of diseases associated with human T-cell leukemia virus type I,” Cancer Science, vol. 98, no. 6, pp. 772–778, 2007. View at Publisher · View at Google Scholar · View at Scopus
  101. K.-I. Ohshima, M. Kikuchi, T. Yoshida, Y.-I. Masuda, and N. Kimura, “Lymph nodes in incipient adult T-cell leukemia-lymphoma with Hodgkin's disease-like histologic features,” Cancer, vol. 67, no. 6, pp. 1622–1628, 1991. View at Google Scholar · View at Scopus
  102. Y. Yamano, N. Araya, T. Sato et al., “Abnormally high levels of virus-infected IFN-γ+CCR4+CD4+CD25+ T cells in a retrovirus-associated neuroinflammatory disorder,” PLoS ONE, vol. 4, no. 8, Article ID e6517, 2009. View at Publisher · View at Google Scholar · View at Scopus
  103. Y. Satou, A. Utsunomiya, J. Tanabe, M. Nakagawa, K. Nosaka, and M. Matsuoka, “HTLV-1 modulates the frequency and phenotype of FoxP3+CD4+ T cells in virus-infected individuals,” Retrovirology, vol. 9, article 46, 2012. View at Publisher · View at Google Scholar · View at Scopus
  104. K. Tsukasaki, C. W. Miller, T. Kubota et al., “Tumor necrosis factor α polymorphism associated with increased susceptibility to development of adult T-cell leukemia/lymphoma in human T-lymphotropic virus type 1 carriers,” Cancer Research, vol. 61, no. 9, pp. 3770–3774, 2001. View at Google Scholar · View at Scopus
  105. J. K. Chan and W. C. Greene, “Dynamic roles for NF-κB in HTLV-I and HIV-1 retroviral pathogenesis,” Immunological Reviews, vol. 246, no. 1, pp. 286–310, 2012. View at Publisher · View at Google Scholar · View at Scopus
  106. D. W. Ballard, “Molecular mechanisms in lymphocyte activation and growth,” Immunologic Research, vol. 23, no. 2-3, pp. 157–166, 2001. View at Publisher · View at Google Scholar · View at Scopus
  107. T. A. Waldmann, S. Dubois, and Y. Tagaya, “Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy,” Immunity, vol. 14, no. 2, pp. 105–110, 2001. View at Google Scholar · View at Scopus
  108. P. Wattre, V. Bert, and D. Hober, “Apoptosis and human viral infections,” Annales de Biologie Clinique, vol. 54, pp. 189–197, 1996. View at Google Scholar
  109. M. Abe, K. Uchihashi, T. Kazuto et al., “Foxp3 expression on normal and leukemic CD4+CD25+ T cells implicated in human T-cell leukemia virus type-1 is inconsistent with Treg cells,” European Journal of Haematology, vol. 81, no. 3, pp. 209–217, 2008. View at Publisher · View at Google Scholar · View at Scopus
  110. G. Roncador, J. F. Garcia, L. Maestre et al., “FOXP3, a selective marker for a subset of adult T-cell leukaemia/lymphoma,” Leukemia, vol. 19, no. 12, pp. 2247–2253, 2005. View at Publisher · View at Google Scholar · View at Scopus
  111. T. Kohno, Y. Yamada, N. Akamatsu et al., “Possible origin of adult T-cell leukemia/lymphoma cells from human T lymphotropic virus type-1-infected regulatory T cells,” Cancer Science, vol. 96, no. 8, pp. 527–533, 2005. View at Publisher · View at Google Scholar · View at Scopus
  112. Y. Yamano, C. J. Cohen, N. Takenouchi et al., “Increased expression of human T lymphocyte virus type I (HTLV-I) Tax11-19 peptide-human histocompatibility leukocyte antigen A*201 complexes on CD4+ CD25+ T cells detected by peptide-specific, major histocompatibility complex-restricted antibodies in patients with HTLV-I-associated neurologic disease,” Journal of Experimental Medicine, vol. 199, no. 10, pp. 1367–1377, 2004. View at Publisher · View at Google Scholar · View at Scopus
  113. Y. Yamano, N. Takenouchi, H.-C. Li et al., “Virus-induced dysfunction of CD4+CD25+ T cells in patients with HTLV-I-associated neuroimmunological disease,” The Journal of Clinical Investigation, vol. 115, no. 5, pp. 1361–1368, 2005. View at Publisher · View at Google Scholar · View at Scopus
  114. C. L. Tendler, S. J. Greenberg, J. D. Burton et al., “Cytokine induction in HTLV-I associated myelopathy and adult T-cell leukemia: alternate molecular mechanisms underlying retroviral pathogenesis,” Journal of Cellular Biochemistry, vol. 46, no. 4, pp. 302–311, 1991. View at Publisher · View at Google Scholar · View at Scopus
  115. E. Ramirez, L. Cartier, L. Rodriguez, C. Alberti, and M. A. Valenzuela, “In vivo fluctuation of Tax, Foxp3, CTLA-4, and GITR mRNA expression in CD4(+)CD25(+) T cells of patients with human T- lymphotropic virus type 1-associated myelopathy,” Brazilian Journal of Medical and Biological Research, vol. 43, no. 11, pp. 1109–1115, 2010. View at Publisher · View at Google Scholar
  116. T. Shimauchi, K. Kabashima, and Y. Tokura, “Adult T-cell leukemia/lymphoma cells from blood and skin tumors express cytotoxic T lymphocyte-associated antigen-4 and Foxp3 but lack suppressor activity toward autologous CD8+ T cells,” Cancer Science, vol. 99, no. 1, pp. 98–106, 2008. View at Publisher · View at Google Scholar · View at Scopus
  117. M. Miyara, Y. Yoshioka, A. Kitoh et al., “Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor,” Immunity, vol. 30, no. 6, pp. 899–911, 2009. View at Publisher · View at Google Scholar · View at Scopus
  118. P. Miyazato and M. Matsuoka, “Human T-cell leukemia virus type 1 and Foxp3 expression: viral strategy in vivo,” International Immunology, vol. 26, no. 8, pp. 419–425, 2014. View at Publisher · View at Google Scholar
  119. Z. Shenghui, H. Yixiang, W. Jianbo et al., “Elevated frequencies of CD4+CD25+CD127lo regulatory T cells is associated to poor prognosis in patients with acute myeloid leukemia,” International Journal of Cancer, vol. 129, no. 6, pp. 1373–1381, 2011. View at Publisher · View at Google Scholar · View at Scopus
  120. L.-F. Lu, T.-H. Thai, D. P. Calado et al., “Foxp3-dependent microRNA155 confers competitive fitness to regulatory T cells by targeting SOCS1 protein,” Immunity, vol. 30, no. 1, pp. 80–91, 2009. View at Publisher · View at Google Scholar · View at Scopus
  121. I. Faraoni, F. R. Antonetti, J. Cardone, and E. Bonmassar, “miR-155 gene: a typical multifunctional microRNA,” Biochimica et Biophysica Acta, vol. 1792, no. 6, pp. 497–505, 2009. View at Publisher · View at Google Scholar · View at Scopus
  122. F. Toulza, K. Nosaka, Y. Tanaka et al., “Human T-lymphotropic virus type 1-induced CC chemokine ligand 22 maintains a high frequency of functional FoxP3+ regulatory T cells,” Journal of Immunology, vol. 185, no. 1, pp. 183–189, 2010. View at Publisher · View at Google Scholar · View at Scopus
  123. M. A. C. de Lafaille and J. J. Lafaille, “Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor?” Immunity, vol. 30, no. 5, pp. 626–635, 2009. View at Publisher · View at Google Scholar · View at Scopus
  124. S. B. Patrie and P. J. Farrell, “The role of Epstein-Barr virus in cancer,” Expert Opinion on Biological Therapy, vol. 6, no. 11, pp. 1193–1205, 2006. View at Publisher · View at Google Scholar · View at Scopus
  125. H. Kanegane, K. Nomura, T. Miyawaki, and G. Tosato, “Biological aspects of Epstein-Barr virus (EBV)-infected lymphocytes in chronic active EBV infection and associated malignancies,” Critical Reviews in Oncology/Hematology, vol. 44, no. 3, pp. 239–249, 2002. View at Publisher · View at Google Scholar · View at Scopus
  126. H. Knecht, C. Berger, S. Rothenberger, B. F. Odermatt, and P. Brousset, “The role of Epstein-Barr virus in neoplastic transformation,” Oncology, vol. 60, no. 4, pp. 289–302, 2001. View at Publisher · View at Google Scholar · View at Scopus
  127. C. A. Kelleher, D. H. Dreyfus, J. F. Jones, and E. W. Gelfand, “EBV infection of T cells: potential role in malignant transformation,” Seminars in Cancer Biology, vol. 7, no. 4, pp. 197–207, 1996. View at Publisher · View at Google Scholar · View at Scopus
  128. L. S. Young and A. B. Rickinson, “Epstein-Barr virus: 40 Years on,” Nature Reviews Cancer, vol. 4, no. 10, pp. 757–768, 2004. View at Publisher · View at Google Scholar · View at Scopus
  129. E. Grywalska, J. Markowicz, P. Grabarczyk, M. Pasiarski, and J. Roliński, “Epstein-Barr virus-associated lymphoproliferative disorders,” Postepy Higieny i Medycyny Doswiadczalnej, vol. 67, pp. 481–490, 2013. View at Publisher · View at Google Scholar · View at Scopus
  130. F. Bray, M. Haugen, T. A. Moger, S. Tretli, O. O. Aalen, and T. Grotmol, “Age-incidence curves of nasopharyngeal carcinoma worldwide: bimodality in low-risk populations and aetiologic implications,” Cancer Epidemiology Biomarkers and Prevention, vol. 17, no. 9, pp. 2356–2365, 2008. View at Publisher · View at Google Scholar · View at Scopus
  131. A. T. C. Chan, “Nasopharyngeal carcinoma,” Annals of Oncology, vol. 21, supplement 7, pp. vii308–vii312, 2010. View at Publisher · View at Google Scholar · View at Scopus
  132. Y.-Y. Yap, S. Hassan, M. Chan, P. K. Choo, and M. Ravichandran, “Epstein-Barr virus DNA detection in the diagnosis of nasopharyngeal carcinoma,” Otolaryngology—Head and Neck Surgery, vol. 136, no. 6, pp. 986–991, 2007. View at Publisher · View at Google Scholar · View at Scopus
  133. D. Liebowitz, “Nasopharyngeal carcinoma: the Epstein-Barr virus association,” Seminars in Oncology, vol. 21, no. 3, pp. 376–381, 1994. View at Google Scholar · View at Scopus
  134. S.-J. Lu, N. E. Day, L. Degos et al., “Linkage of a nasopharyngeal carcinoma susceptibility locus to the HLA region,” Nature, vol. 346, no. 6283, pp. 470–471, 1990. View at Publisher · View at Google Scholar · View at Scopus
  135. X. Zheng, L. Yan, B. Nilsson, G. Eklund, and B. Drettner, “Epstein-Barr virus infection, salted fish and nasopharyngeal carcinoma. A case-control study in Southern China,” Acta Oncologica, vol. 33, no. 8, pp. 867–872, 1994. View at Publisher · View at Google Scholar · View at Scopus
  136. L. Gallicchio, G. Matanoski, X. Tao et al., “Adulthood consumption of preserved and nonpreserved vegetables and the risk of nasopharyngeal carcinoma: a systematic review,” International Journal of Cancer, vol. 119, no. 5, pp. 1125–1135, 2006. View at Publisher · View at Google Scholar · View at Scopus
  137. A. Hildesheim and C. P. Wang, “Genetic predisposition factors and nasopharyngeal carcinoma risk: a review of epidemiological association studies, 2000–2011. Rosetta Stone for NPC: genetics, viral infection, and other environmental factors,” Seminars in Cancer Biology, vol. 22, no. 2, pp. 107–116, 2012. View at Publisher · View at Google Scholar · View at Scopus
  138. P. G. Knox, Q.-X. Li, A. B. Rickinson, and L. S. Young, “In vitro production of stable Epstein-Barr virus-positive epithelial cell clones which resemble the virus: cell interaction observed in nasopharyngeal carcinoma,” Virology, vol. 215, no. 1, pp. 40–50, 1996. View at Publisher · View at Google Scholar · View at Scopus
  139. G. Niedobitek, L. S. Young, C. K. Sam, L. Brooks, U. Prasad, and A. B. Rickinson, “Expression of Epstein-Barr virus genes and of lymphocyte activation molecules in undifferentiated nasopharyngeal carcinomas,” The American Journal of Pathology, vol. 140, no. 4, pp. 879–887, 1992. View at Google Scholar · View at Scopus
  140. R. Pathmanathan, U. Prasad, R. Sadler, K. Flynn, and N. Raab-Traub, “Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma,” The New England Journal of Medicine, vol. 333, no. 11, pp. 693–698, 1995. View at Publisher · View at Google Scholar · View at Scopus
  141. S. Depil, O. Moralès, and C. Auriault, “Hodgkin's disease and Epstein-Barr virus,” Annales de Biologie Clinique, vol. 62, no. 6, pp. 639–648, 2004. View at Google Scholar · View at Scopus
  142. R. F. Jarrett, G. L. Stark, J. White et al., “Impact of tumor Epstein-Barr virus status on presenting features and outcome in age-defined subgroups of patients with classic Hodgkin lymphoma: a population-based study,” Blood, vol. 106, no. 7, pp. 2444–2451, 2005. View at Publisher · View at Google Scholar · View at Scopus
  143. P. Busson, K. Braham, G. Ganem et al., “Epstein-Barr virus-containing epithelial cells from nasopharyngeal carcinoma produce interleukin 1 alpha.,” Proceedings of the National Academy of Sciences of the United States of America, vol. 84, no. 17, pp. 6262–6266, 1987. View at Publisher · View at Google Scholar · View at Scopus
  144. Y.-T. Huang, T.-S. Sheen, C.-L. Chen et al., “Profile of cytokine expression in nasopharyngeal carcinomas: a distinct expression of interleukin 1 in tumor and CD4+ T cells,” Cancer Research, vol. 59, no. 7, pp. 1599–1605, 1999. View at Google Scholar · View at Scopus
  145. K. F. Tang, S. Y. Tan, S. H. Chan et al., “A distinct expression of CC chemokines by macrophages in nasopharyngeal carcinoma: Implication for the intense tumor infiltration by T lymphocytes and macrophages,” Human Pathology, vol. 32, no. 1, pp. 42–49, 2001. View at Publisher · View at Google Scholar · View at Scopus
  146. M. Teichmann, B. Meyer, A. Beck, and G. Niedobitek, “Expression of the interferon-inducible chemokine IP-10 (CXCL10), a chemokine with proposed anti-neoplastic functions, in Hodgkin lymphoma and nasopharyngeal carcinoma,” The Journal of Pathology, vol. 206, no. 1, pp. 68–75, 2005. View at Publisher · View at Google Scholar · View at Scopus
  147. P. Herait, G. Ganem, M. Lipinski et al., “Lymphocyte subsets in tumour of patients with undifferentiated nasopharyngeal carcinoma: presence of lymphocytes with the phenotype of activated T cells,” The British Journal of Cancer, vol. 55, no. 2, pp. 135–139, 1987. View at Publisher · View at Google Scholar · View at Scopus
  148. A. Agathanggelou, G. Niedobitek, R. Chen, J. Nicholls, W. Yin, and L. S. Young, “Expression of immune regulatory molecules in Epstein-Barr virus-associated nasopharyngeal carcinomas with prominent lymphoid stroma evidence for a functional interaction between epithelial tumor cells and infiltrating lymphoid cells,” The American Journal of Pathology, vol. 147, no. 4, pp. 1152–1160, 1995. View at Google Scholar · View at Scopus
  149. L. Ferradini, S. Miescher, M. Stoeck et al., “Cytotoxic potential despite impaired activation pathways in T lymphocytes infiltrating nasopharyngeal carcinoma,” International Journal of Cancer, vol. 47, no. 3, pp. 362–370, 1991. View at Publisher · View at Google Scholar · View at Scopus
  150. Y. S. Zong, C. Q. Zhang, F. Zhang et al., “Infiltrating lymphocytes and accessory cells in nasopharyngeal carcinoma,” Japanese Journal of Cancer Research, vol. 84, no. 8, pp. 900–905, 1993. View at Publisher · View at Google Scholar · View at Scopus
  151. A. Giannini, S. Bianchi, L. Messerini et al., “Prognostic significance of accessory cells and lymphocytes in nasopharyngeal carcinoma,” Pathology Research and Practice, vol. 187, no. 4, pp. 496–502, 1991. View at Publisher · View at Google Scholar · View at Scopus
  152. C.-M. Liu, J.-J. Ko, C.-T. Shun, T.-Y. Hsiao, and T.-S. Sheen, “Soluble adhesion molecules and cytokines in tumor-associated tissue eosinophilia of nasopharyngeal carcinoma,” Acta Oto-Laryngologica, vol. 121, no. 4, pp. 534–538, 2001. View at Publisher · View at Google Scholar · View at Scopus
  153. L.-C. Chen, L.-J. Wang, N.-M. Tsang et al., “Tumour inflammasome-derived IL-1β recruits neutrophils and improves local recurrence-free survival in EBV-induced nasopharyngeal carcinoma,” EMBO Molecular Medicine, vol. 4, no. 12, pp. 1276–1293, 2012. View at Publisher · View at Google Scholar · View at Scopus
  154. H. Hu, K. F. Tang, Y. N. Chua et al., “Expression of interleukin-18 by nasopharyngeal carcinoma cells: a factor that possibly initiates the massive leukocyte infiltration,” Human Pathology, vol. 35, no. 6, pp. 722–728, 2004. View at Publisher · View at Google Scholar · View at Scopus
  155. M. Samoszuk and L. Nansen, “Detection of interleukin-5 messenger RNA in Reed-Sternberg cells of Hodgkin's disease with eosinophilia,” Blood, vol. 75, no. 1, pp. 13–16, 1990. View at Google Scholar · View at Scopus
  156. H. Hanamoto, T. Nakayama, H. Miyazato et al., “Expression of CCL28 by Reed-Sternberg cells defines a major subtype of classical Hodgkin's disease with frequent infiltration of eosinophils and/or plasma cells,” The American Journal of Pathology, vol. 164, no. 3, pp. 997–1006, 2004. View at Publisher · View at Google Scholar · View at Scopus
  157. F. Jundt, I. Anagnostopoulos, K. Bommert et al., “Hodgkin/Reed-Sternberg cells induce fibroblasts to secrete eotaxin, a potent chemoattractant for T cells and eosinophils,” Blood, vol. 94, no. 6, pp. 2065–2071, 1999. View at Google Scholar · View at Scopus
  158. H. D. Foss, H. Herbst, E. Oelmann et al., “Lymphotoxin, tumour necrosis factor and interleukin-6 gene transcripts are present in Hodgkin and Reed-Sternberg cells of most Hodgkin's disease cases,” British Journal of Haematology, vol. 84, no. 4, pp. 627–635, 1993. View at Publisher · View at Google Scholar · View at Scopus
  159. O. Micheau and J. Tschopp, “Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes,” Cell, vol. 114, no. 2, pp. 181–190, 2003. View at Publisher · View at Google Scholar · View at Scopus
  160. B. C. Barnhart and M. E. Peter, “The TNF receptor 1: a split personality complex,” Cell, vol. 114, no. 2, pp. 148–150, 2003. View at Publisher · View at Google Scholar · View at Scopus
  161. M. Hinz, P. Lemke, I. Anagnostopoulos et al., “Nuclear factor κb-dependent gene expression profiling of Hodgkin's disease tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activity,” The Journal of Experimental Medicine, vol. 196, no. 5, pp. 605–617, 2002. View at Publisher · View at Google Scholar · View at Scopus
  162. H.-D. Foss, M. Hummel, S. Gottstein et al., “Frequent expression of IL-7 gene transcripts in tumor cells of classical Hodgkin's disease,” The American Journal of Pathology, vol. 146, no. 1, pp. 33–39, 1995. View at Google Scholar · View at Scopus
  163. M. Jucker, H. Abts, D. Eick, G. M. Lenoir, and H. Tesch, “Over-expression of lck in Burkitt's lymphoma cell lines,” Leukemia, vol. 5, no. 6, pp. 528–530, 1991. View at Google Scholar · View at Scopus
  164. M. Malec, M. Söderqvist, A. Sirsjö et al., “Real-time polymerase chain reaction determination of cytokine mRNA expression profiles in Hodgkin's lymphoma,” Haematologica, vol. 89, no. 6, pp. 679–685, 2004. View at Google Scholar · View at Scopus
  165. U. Kapp, W. C. Yeh, B. Patterson et al., “Interleukin 13 is secreted by and stimulates the growth of Hodgkin and Reed-Sternberg cells,” Journal of Experimental Medicine, vol. 189, no. 12, pp. 1939–1946, 1999. View at Publisher · View at Google Scholar · View at Scopus
  166. K. Ohshima, M. Akaiwa, R. Umeshita, J. Suzumiya, K. Izuhara, and M. Kikuchi, “Interleukin-13 and interleukin-13 receptor in Hodgkin's disease: possible autocrine mechanism and involvement in fibrosis,” Histopathology, vol. 38, no. 4, pp. 368–375, 2001. View at Publisher · View at Google Scholar · View at Scopus
  167. B. F. Skinnider and T. W. Mak, “The role of cytokines in classical Hodgkin lymphoma,” Blood, vol. 99, no. 12, pp. 4283–4297, 2002. View at Publisher · View at Google Scholar · View at Scopus
  168. E. Maggio, A. van den Berg, A. Diepstra, J. Kluiver, L. Visser, and S. Poppema, “Chemokines, cytokines and their receptors in Hodgkin's lymphoma cell lines and tissues,” Annals of Oncology, vol. 13, supplement 1, pp. 52–56, 2002. View at Publisher · View at Google Scholar · View at Scopus
  169. U. E. Höpken, H.-D. Foss, D. Meyer et al., “Up-regulation of the chemokine receptor CCR7 in classical but not in lymphocyte-predominant Hodgkin disease correlates with distinct dissemination of neoplastic cells in lymphoid organs,” Blood, vol. 99, no. 4, pp. 1109–1116, 2002. View at Publisher · View at Google Scholar · View at Scopus
  170. J. Schwaller, A. Tobler, G. Niklaus et al., “Interleukin-12 expression in human lymphomas and nonneoplastic lymphoid disorders,” Blood, vol. 85, no. 8, pp. 2182–2188, 1995. View at Google Scholar · View at Scopus
  171. A. van Den Berg, E. Maggio, R. Rust, K. Kooistra, A. Diepstra, and S. Poppema, “Clonal relation in a case of CLL, ALCL, and Hodgkin composite lymphoma,” Blood, vol. 100, no. 4, pp. 1425–1429, 2002. View at Google Scholar · View at Scopus
  172. M. Yao, K. Ohshima, J. Suzumiya, T. Kume, T. Shiroshita, and M. Kikuchi, “Interleukin-10 expression and cytotoxic-T-cell response in Epstein-Barr-virus-associated nasopharyngeal carcinoma,” International Journal of Cancer, vol. 72, pp. 398–402, 1997. View at Google Scholar
  173. S. Fujieda, K. Lee, H. Sunaga et al., “Staining of interleukin-10 predicts clinical outcome in patients with nasopharyngeal carcinoma,” Cancer, vol. 85, no. 7, pp. 1439–1445, 1999. View at Google Scholar
  174. E. Özyar, A. Ayhan, A. F. Korcum, and I. L. Atahan, “Prognostic role of Ebstein-Barr virus latent membrane protein-1 and Interleukin-10 expression in patients with nasopharyngeal carcinoma,” Cancer Investigation, vol. 22, no. 4, pp. 483–491, 2004. View at Publisher · View at Google Scholar · View at Scopus
  175. A. Beck, D. Pzolt, G. G. Grabenbauer et al., “Expression of cytokine and chemokine genes in Epstein-Barr virus-associated nasopharyngeal carcinoma: comparison with Hodgkin's disease,” The Journal of Pathology, vol. 194, no. 2, pp. 145–151, 2001. View at Publisher · View at Google Scholar · View at Scopus
  176. K.-M. Lau, S. H. Cheng, K. W. Lo et al., “Increase in circulating Foxp3 + CD4 + CD25high regulatory T cells in nasopharyngeal carcinoma patients,” British Journal of Cancer, vol. 96, no. 4, pp. 617–622, 2007. View at Publisher · View at Google Scholar · View at Scopus
  177. N. A. Marshall, L. E. Christie, L. R. Munro et al., “Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma,” Blood, vol. 103, no. 5, pp. 1755–1762, 2004. View at Publisher · View at Google Scholar · View at Scopus
  178. C.-T. Huang, C. J. Workman, D. Flies et al., “Role of LAG-3 in regulatory T cells,” Immunity, vol. 21, no. 4, pp. 503–513, 2004. View at Publisher · View at Google Scholar · View at Scopus
  179. M. K. Gandhi, E. Lambley, J. Duraiswamy et al., “Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T-cell function in Hodgkin lymphoma patients,” Blood, vol. 108, no. 7, pp. 2280–2289, 2006. View at Publisher · View at Google Scholar · View at Scopus
  180. S. V. Kui, G. Peng, Z. Guo et al., “Functional characterization of EBV-encoded nuclear antigen 1-specific CD4+ helper and regulatory T cells elicited by in vitro peptide stimulation,” Cancer Research, vol. 65, no. 4, pp. 1577–1586, 2005. View at Publisher · View at Google Scholar · View at Scopus
  181. D. F. Dukers, P. Meij, M. B. H. J. Vervoort et al., “Direct immunosuppressive effects of EBV-encoded latent membrane protein 1,” Journal of Immunology, vol. 165, no. 2, pp. 663–670, 2000. View at Publisher · View at Google Scholar · View at Scopus
  182. K.-P. Chang, S.-P. Hao, J.-H. Chang et al., “Macrophage inflammatory protein-3α is a novel serum marker for nasopharyngeal carcinoma detection and prediction of treatment outcomes,” Clinical Cancer Research, vol. 14, no. 21, pp. 6979–6987, 2008. View at Publisher · View at Google Scholar · View at Scopus
  183. A. L. Chapman, A. B. Rickinson, W. A. Thomas, R. F. Jarrett, J. Crocker, and S. P. Lee, “Epstein-barr virus-specific cytotoxic T lymphocyte responses in the blood and tumor site of Hodgkin's disease patients: implications for a T-cell-based therapy,” Cancer Research, vol. 61, no. 16, pp. 6219–6226, 2001. View at Google Scholar · View at Scopus
  184. S. Poppema, M. Potters, R. Emmens, L. Visser, and A. van den Berg, “Immune reactions in classical Hodgkin's lymphoma,” Seminars in Hematology, vol. 36, no. 3, pp. 253–259, 1999. View at Google Scholar · View at Scopus
  185. T. J. Curiel, G. Coukos, L. Zou et al., “Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival,” Nature Medicine, vol. 10, no. 9, pp. 942–949, 2004. View at Publisher · View at Google Scholar · View at Scopus
  186. J. D. Fontenot, M. A. Gavin, and A. Y. Rudensky, “Foxp3 programs the development and function of CD4+CD25+ regulatory T cells,” Nature Immunology, vol. 4, no. 4, pp. 330–336, 2003. View at Publisher · View at Google Scholar · View at Scopus
  187. W.-Z. Wei, G. P. Morris, and Y.-C. M. Kong, “Anti-tumor immunity and autoimmunity: a balancing act of regulatory T cells,” Cancer Immunology, Immunotherapy, vol. 53, no. 2, pp. 73–78, 2004. View at Publisher · View at Google Scholar · View at Scopus
  188. S. Baráth, M. Aleksza, K. Keresztes et al., “Immunoregulatory T cells in the peripheral blood of patients with Hodgkin's lymphoma,” Acta Haematologica, vol. 116, no. 3, pp. 181–185, 2006. View at Publisher · View at Google Scholar · View at Scopus
  189. T. Alvaro, M. Lejeune, M. T. Salvado et al., “Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells,” Clinical Cancer Research, vol. 11, pp. 1467–1473, 2005. View at Google Scholar
  190. O. Morales, D. Mrizak, V. François et al., “Epstein–Barr virus infection induces an increase of T regulatory type 1 cells in Hodgkin lymphoma patients,” British Journal of Haematology, vol. 166, no. 6, pp. 875–890, 2014. View at Publisher · View at Google Scholar